Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2013

Open Access 01-12-2013 | Research article

Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival

Authors: Lars L Eftang, Ying Esbensen, Tone M Tannæs, Gustav P Blom, Ida RK Bukholm, Geir Bukholm

Published in: BMC Cancer | Issue 1/2013

Login to get access

Abstract

Background

The genetic changes in gastric adenocarcinoma are extremely complex and reliable tumor markers have not yet been identified. There are also remarkable geographical differences in the distribution of this disease. Our aim was to identify the most differentially regulated genes in 20 gastric adenocarcinomas from a Norwegian selection, compared to matched normal mucosa, and we have related our findings to prognosis, survival and chronic Helicobacter pylori infection.

Methods

Biopsies from gastric adenocarcinomas and adjacent normal gastric mucosa were obtained from 20 patients immediately following surgical resection of the tumor. Whole genome, cDNA microarray analysis was performed on the RNA isolated from the sample pairs to compare the gene expression profiles between the tumor against matched mucosa. The samples were microscopically examined to classify gastritis. The presence of H. pylori was examined using microscopy and immunohistochemistry.

Results

130 genes showed differential regulation above a predefined cut-off level. Interleukin-8 (IL-8) and Claudin-1 (CLDN1) were the most consistently up-regulated genes in the tumors. Very high CLDN1 expression in the tumor was identified as an independent and significant predictor gene of reduced post-operative survival. There were distinctly different expression profiles between the tumor group and the control mucosa group, and the histological subsets of mixed type, diffuse type and intestinal type cancer demonstrated further sub-clustering. Up-regulated genes were mapped to cell-adhesion, collagen-related processes and angiogenesis, whereas normal intestinal functions such as digestion and excretion were associated with down-regulated genes. We relate the current findings to our previous study on the gene response of gastric epithelial cells to H. pylori infection.

Conclusions

CLDN1 was highly up-regulated in gastric cancer, and CLDN1 expression was independently associated with a poor post-operative prognosis, and may have important prognostic value. IL-8 and CLDN1 may represent central links between the gene response seen in acute H. pylori infection of gastric epithelial cells, and ultimately gastric cancer.
Appendix
Available only for authorised users
Literature
1.
Cancer registery of Norway: Cancer in Norway 2010, Cancer incidence, mortality, survival and prevalence in Norway. 2013, Oslo, Norway: Cancer Registry of Norway
2.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10. Lyon. 2010, France: International Agency for Research on Cancer, http://​globocan.​iarc.​fr,
3.
Takeno A, Takemasa I, Seno S, Yamasaki M, Motoori M, Miyata H, et al: Gene expression profile prospectively predicts peritoneal relapse after curative surgery of gastric cancer. Ann Surg Oncol. 2010, 17: 1033-1042. 10.1245/s10434-009-0854-1.CrossRefPubMed
4.
Teramoto K, Tada M, Tamoto E, Abe M, Kawakami A, Komuro K, et al: Prediction of lymphatic invasion/lymph node metastasis, recurrence, and survival in patients with gastric cancer by cDNA array-based expression profiling. J Surg Res. 2005, 124: 225-236. 10.1016/j.jss.2004.10.003.CrossRefPubMed
5.
Chen CN, Lin JJ, Chen JJ, Lee PH, Yang CY, Kuo ML, et al: Gene expression profile predicts patient survival of gastric cancer after surgical resection. J Clin Oncol. 2005, 23: 7286-7295. 10.1200/JCO.2004.00.2253.CrossRefPubMed
6.
Motoori M, Takemasa I, Doki Y, Saito S, Miyata H, Takiguchi S, et al: Prediction of peritoneal metastasis in advanced gastric cancer by gene expression profiling of the primary site. Eur J Cancer. 2006, 42: 1897-1903. 10.1016/j.ejca.2006.04.007.CrossRefPubMed
7.
Motoori M, Takemasa I, Yano M, Saito S, Miyata H, Takiguchi S, et al: Prediction of recurrence in advanced gastric cancer patients after curative resection by gene expression profiling. Int J Cancer. 2005, 114: 963-968. 10.1002/ijc.20808.CrossRefPubMed
8.
Cho JY, Lim JY, Cheong JH, Park YY, Yoon SL, Kim SM, et al: Gene expression signature-based prognostic risk score in gastric cancer. Clin Cancer Res. 2011, 17: 1850-1857. 10.1158/1078-0432.CCR-10-2180.CrossRefPubMedPubMedCentral
9.
Lauren P: The two histological main types of gastric carcinoma: Diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. Acta Pathol Microbiol Scand. 1965, 64: 31-49.PubMed
10.
11.
12.
Hudler P: Genetic aspects of gastric cancer instability. Sci World J. 2012, 2012: 761909-CrossRef
13.
Nagini S: Carcinoma of the stomach: a review of epidemiology, pathogenesis, molecular genetics and chemoprevention. World J Gastrointest Oncol. 2012, 4: 156-169. 10.4251/wjgo.v4.i7.156.CrossRefPubMedPubMedCentral
14.
Zheng HC, Li XH, Hara T, Masuda S, Yang XH, Guan YF, et al: Mixed-type gastric carcinomas exhibit more aggressive features and indicate the histogenesis of carcinomas. Virchows Arch. 2008, 452: 525-534. 10.1007/s00428-007-0572-7.CrossRefPubMedPubMedCentral
15.
Yang X, Takano Y, Zheng HC: The pathobiological features of gastrointestinal cancers (Review). Oncol Lett. 2012, 3: 961-969.PubMedPubMedCentral
16.
Tan IB, Ng I, Tai WM, Tan P: Understanding the genetic basis of gastric cancer: Recent advances. Expert Rev Gastroenterol Hepatol. 2012, 6: 335-341. 10.1586/egh.12.7.CrossRefPubMed
17.
Eftang LL, Esbensen Y, Tannaes TM, Bukholm IR, Bukholm G: Interleukin-8 is the single most up-regulated gene in whole genome profiling of H. pylori exposed gastric epithelial cells. BMC Microbiol. 2012, 12: 9-10.1186/1471-2180-12-9.CrossRefPubMedPubMedCentral
18.
Sipponen P, Price AB: The Sydney System for classification of gastritis 20 years ago. J Gastroenterol Hepatol. 2011, 26 (Suppl 1): 31-34.CrossRefPubMed
19.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol. 1996, 20: 1161-1181.CrossRefPubMed
20.
21.
22.
R: Development core team: A language and environment for statistical computing. 2008, Vienna, Austria: R Foundation for Statistical Computing
23.
Gentleman RC, Carey VJ, Bates DM, Bolstad B, Dettling M, Dudoit S, et al: Bioconductor: open software development for computational biology and bioinformatics. Genome Biol. 2004, 5: R80-10.1186/gb-2004-5-10-r80.CrossRefPubMedPubMedCentral
24.
Dunning MJ, Barbosa-Morais NL, Lynch AG, Tavare S, Ritchie ME: Statistical issues in the analysis of Illumina data. BMC Bioinformatics. 2008, 9: 85-10.1186/1471-2105-9-85.CrossRefPubMedPubMedCentral
25.
Cairns JM, Dunning MJ, Ritchie ME, Russell R, Lynch AG: BASH: a tool for managing BeadArray spatial artefacts. Bioinformatics. 2008, 24: 2921-2922. 10.1093/bioinformatics/btn557.CrossRefPubMedPubMedCentral
26.
Stavrum AK, Petersen K, Jonassen I, Dysvik B: Analysis of gene-expression data using J-Express. Curr Protoc Bioinformatics. 2008, Chapter 7: Unit 7.3
27.
Breitling R, Armengaud P, Amtmann A, Herzyk P: Rank products: a simple, yet powerful, new method to detect differentially regulated genes in replicated microarray experiments. FEBS Lett. 2004, 573: 83-92. 10.1016/j.febslet.2004.07.055.CrossRefPubMed
28.
Draghici S, Khatri P, Bhavsar P, Shah A, Krawetz SA, Tainsky MA: Onto-tools, the toolkit of the modern biologist: Onto-express, onto-compare, onto-design and onto-translate. Nucleic Acids Res. 2003, 31: 3775-3781. 10.1093/nar/gkg624.CrossRefPubMedPubMedCentral
29.
Draghici S, Khatri P, Tarca AL, Amin K, Done A, Voichita C, et al: A systems biology approach for pathway level analysis. Genome Res. 2007, 17: 1537-1545. 10.1101/gr.6202607.CrossRefPubMedPubMedCentral
30.
31.
Khatri P, Sellamuthu S, Malhotra P, Amin K, Done A, Draghici S: Recent additions and improvements to the Onto-Tools. Nucleic Acids Res. 2005, 33: W762-W765. 10.1093/nar/gki472.CrossRefPubMedPubMedCentral
32.
33.
Jung H, Jun KH, Jung JH, Chin HM, Park WB: The expression of claudin-1, claudin-2, claudin-3, and claudin-4 in gastric cancer tissue. J Surg Res. 2011, 167: e185-e191. 10.1016/j.jss.2010.02.010.CrossRefPubMed
34.
Iravani O, Tay BW, Chua PJ, Yip GW, Bay BH: Claudins and gastric carcinogenesis. Exp Biol Med (Maywood). 2013, 238: 344-349. 10.1177/1535370213477981.CrossRef
35.
Liu Y, Wang L, Lin XY, Wang J, Yu JH, Miao Y, et al: Anti-apoptotic effect of claudin-1 on TNF-alpha-induced apoptosis in human breast cancer MCF-7 cells. Tumour Biol. 2012, 33: 2307-2315. 10.1007/s13277-012-0493-1.CrossRefPubMed
36.
Zavala-Zendejas VE, Torres-Martinez AC, Salas-Morales B, Fortoul TI, Montano LF, Rendon-Huerta EP: Claudin-6, 7, or 9 overexpression in the human gastric adenocarcinoma cell line AGS increases its invasiveness, migration, and proliferation rate. Cancer Invest. 2011, 29: 1-11. 10.3109/07357907.2010.512594.CrossRefPubMed
37.
Chang TL, Ito K, Ko TK, Liu Q, Salto-Tellez M, Yeoh KG, et al: Claudin-1 has tumor suppressive activity and is a direct target of RUNX3 in gastric epithelial cells. Gastroenterology. 2010, 138: 255-265. 10.1053/j.gastro.2009.08.044.CrossRefPubMed
38.
Resnick MB, Gavilanez M, Newton E, Konkin T, Bhattacharya B, Britt DE, et al: Claudin expression in gastric adenocarcinomas: a tissue microarray study with prognostic correlation. Hum Pathol. 2005, 36: 886-892. 10.1016/j.humpath.2005.05.019.CrossRefPubMed
39.
Wu YL, Zhang S, Wang GR, Chen YP: Expression transformation of claudin-1 in the process of gastric adenocarcinoma invasion. World J Gastroenterol. 2008, 14: 4943-4948. 10.3748/wjg.14.4943.CrossRefPubMedPubMedCentral
40.
Shibutani M, Noda E, Maeda K, Nagahara H, Ohtani H, Hirakawa K: Low expression of claudin-1 and presence of poorly-differentiated tumor clusters correlate with poor prognosis in colorectal cancer. Anticancer Res. 2013, 33: 3301-3306.PubMed
41.
Nakagawa S, Miyoshi N, Ishii H, Mimori K, Tanaka F, Sekimoto M, et al: Expression of CLDN1 in colorectal cancer: a novel marker for prognosis. Int J Oncol. 2011, 39: 791-796.PubMed
42.
Song X, Li X, Tang Y, Chen H, Wong B, Wang J, et al: Expression of claudin-2 in the multistage process of gastric carcinogenesis. Histol Histopathol. 2008, 23: 673-682.PubMed
43.
Amasheh S, Meiri N, Gitter AH, Schoneberg T, Mankertz J, Schulzke JD, et al: Claudin-2 expression induces cation-selective channels in tight junctions of epithelial cells. J Cell Sci. 2002, 115: 4969-4976. 10.1242/jcs.00165.CrossRefPubMed
44.
Furuse M, Furuse K, Sasaki H, Tsukita S: Conversion of zonulae occludentes from tight to leaky strand type by introducing claudin-2 into Madin-Darby canine kidney I cells. J Cell Biol. 2001, 153: 263-272. 10.1083/jcb.153.2.263.CrossRefPubMedPubMedCentral
45.
Mima S, Takehara M, Takada H, Nishimura T, Hoshino T, Mizushima T: NSAIDs suppress the expression of claudin-2 to promote invasion activity of cancer cells. Carcinogenesis. 2008, 29: 1994-2000. 10.1093/carcin/bgn134.CrossRefPubMed
46.
Rendon-Huerta E, Teresa F, Teresa GM, Xochitl GS, Georgina AF, Veronica ZZ, et al: Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J Gastrointest Cancer. 2010, 41: 52-59. 10.1007/s12029-009-9110-y.CrossRefPubMed
47.
Park JY, Park KH, Oh TY, Hong SP, Jeon TJ, Kim CH, et al: Up-regulated claudin 7 expression in intestinal-type gastric carcinoma. Oncol Rep. 2007, 18: 377-382.PubMed
48.
Johnson AH, Frierson HF, Zaika A, Powell SM, Roche J, Crowe S, et al: Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am J Pathol. 2005, 167: 577-584. 10.1016/S0002-9440(10)62999-9.CrossRefPubMedPubMedCentral
49.
Xuan J, Deguchi R, Yanagi H, Ozawa H, Urano T, Ogawa Y, et al: Relationship between gastric mucosal IL-8 levels and histological gastritis in patients with Helicobacter pylori infection. Tokai J Exp Clin Med. 2005, 30: 83-88.PubMed
50.
Chiba T, Marusawa H, Seno H, Watanabe N: Mechanism for gastric cancer development by Helicobacter pylori infection. J Gastroenterol Hepatol. 2008, 23: 1175-1181. 10.1111/j.1440-1746.2008.05472.x.CrossRefPubMed
51.
Koch AE, Polverini PJ, Kunkel SL, Harlow LA, DiPietro LA, Elner VM, et al: Interleukin-8 as a macrophage-derived mediator of angiogenesis. Science. 1992, 258: 1798-1801. 10.1126/science.1281554.CrossRefPubMed
52.
Hu DE, Hori Y, Fan TP: Interleukin-8 stimulates angiogenesis in rats. Inflammation. 1993, 17: 135-143. 10.1007/BF00916100.CrossRefPubMed
53.
Heidemann J, Ogawa H, Dwinell MB, Rafiee P, Maaser C, Gockel HR, et al: Angiogenic effects of interleukin 8 (CXCL8) in human intestinal microvascular endothelial cells are mediated by CXCR2. J Biol Chem. 2003, 278: 8508-8515. 10.1074/jbc.M208231200.CrossRefPubMed
54.
Kitadai Y, Takahashi Y, Haruma K, Naka K, Sumii K, Yokozaki H, et al: Transfection of interleukin-8 increases angiogenesis and tumorigenesis of human gastric carcinoma cells in nude mice. Br J Cancer. 1999, 81: 647-653. 10.1038/sj.bjc.6690742.CrossRefPubMedPubMedCentral
55.
Kuai WX, Wang Q, Yang XZ, Zhao Y, Yu R, Tang XJ: Interleukin-8 associates with adhesion, migration, invasion and chemosensitivity of human gastric cancer cells. World J Gastroenterol. 2012, 18: 979-985. 10.3748/wjg.v18.i9.979.CrossRefPubMedPubMedCentral
56.
Ju D, Sun D, Xiu L, Meng X, Zhang C, Wei P: Interleukin-8 is associated with adhesion, migration and invasion in human gastric cancer SCG-7901 cells. Med Oncol. 2012, 29: 91-99. 10.1007/s12032-010-9780-0.CrossRefPubMed
57.
Schraufstatter IU, Chung J, Burger M: IL-8 activates endothelial cell CXCR1 and CXCR2 through Rho and Rac signaling pathways. Am J Physiol Lung Cell Mol Physiol. 2001, 280: L1094-L1103.PubMed
58.
Bartchewsky W, Martini MR, Masiero M, Squassoni AC, Alvarez MC, Ladeira MS, et al: Effect of Helicobacter pylori infection on IL-8, IL-1beta and COX-2 expression in patients with chronic gastritis and gastric cancer. Scand J Gastroenterol. 2009, 44: 153-161. 10.1080/00365520802530853.CrossRefPubMed
59.
Noshiro M, Kusugami K, Sakai T, Imada A, Ando T, Ina K, et al: Gastric metaplasia in the duodenal bulb shows increased mucosal interleukin-8 activity in Helicobacter pylori-positive duodenal ulcer patients. Scand J Gastroenterol. 2000, 35: 482-489. 10.1080/003655200750023732.CrossRefPubMed
60.
IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. Lyon: Schistosomes, liver flukes and Helicobacter pylori. IARC Monogr Eval Carcinog Risks Hum. 1994, 61: 1-241.
61.
Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, et al: Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci. 2007, 98: 790-794. 10.1111/j.1349-7006.2007.00478.x.CrossRefPubMed
62.
Kang HY, Kim N, Park YS, Hwang JH, Kim JW, Jeong SH, et al: Progression of atrophic gastritis and intestinal metaplasia drives Helicobacter pylori out of the gastric mucosa. Dig Dis Sci. 2006, 51: 2310-2315. 10.1007/s10620-006-9276-0.CrossRefPubMed
63.
Economescu MC, Necula LG, Dragu D, Badea L, Dima SO, Tudor S, et al: Identification of potential biomarkers for early and advanced gastric adenocarcinoma detection. Hepatogastroenterology. 2010, 57: 1453-1464.
64.
Su CQ, Qiu H, Zhang Y: Localization of keratin mRNA and collagen I mRNA in gastric cancer by in situ hybridization and hybridization electron microscopy. World J Gastroenterol. 1999, 5: 527-530.CrossRefPubMedPubMedCentral
65.
Pluciennik E, Krol M, Nowakowska M, Kusinska R, Potemski P, Kordek R, et al: Breast cancer relapse prediction based on multi-gene RT-PCR algorithm. Med Sci Monit. 2010, 16: CR132-CR136.PubMed
66.
Miyata Y, Iwata T, Maruta S, Kanda S, Nishikido M, Koga S, et al: Expression of matrix metalloproteinase-10 in renal cell carcinoma and its prognostic role. Eur Urol. 2007, 52: 791-797. 10.1016/j.eururo.2006.12.028.CrossRefPubMed
67.
Zhao ZS, Chu YQ, Ye ZY, Wang YY, Tao HQ: Overexpression of matrix metalloproteinase 11 in human gastric carcinoma and its clinicopathologic significance. Hum Pathol. 2010, 41: 686-696. 10.1016/j.humpath.2009.10.010.CrossRefPubMed
68.
Yang YH, Deng H, Li WM, Zhang QY, Hu XT, Xiao B, et al: Identification of matrix metalloproteinase 11 as a predictive tumor marker in serum based on gene expression profiling. Clin Cancer Res. 2008, 14: 74-81. 10.1158/1078-0432.CCR-07-1179.CrossRefPubMed
69.
Yamashita K, Azumano I, Mai M, Okada Y: Expression and tissue localization of matrix metalloproteinase 7 (matrilysin) in human gastric carcinomas. Implications for vessel invasion and metastasis. Int J Cancer. 1998, 79: 187-194. 10.1002/(SICI)1097-0215(19980417)79:2<187::AID-IJC15>3.0.CO;2-7.CrossRefPubMed
Metadata
Title
Up-regulation of CLDN1 in gastric cancer is correlated with reduced survival
Authors
Lars L Eftang
Ying Esbensen
Tone M Tannæs
Gustav P Blom
Ida RK Bukholm
Geir Bukholm
Publication date
01-12-2013
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2013
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-13-586

Other articles of this Issue 1/2013

BMC Cancer 1/2013 Go to the issue

Research article

Association between polymorphisms in ERCC2 gene and oral cancer risk: evidence from a meta-analysis

Research article

Assessment of HER2 status in breast cancer: overall positivity rate and accuracy by fluorescence in situ hybridization and immunohistochemistry in a single institution over 12 years: a quality control study

Case report

Small-cell lung cancer with a rare epidermal growth factor receptor gene mutation showing “wax-and-wane” transformation

Research article

S-1 combined with docetaxel following doxorubicin plus cyclophosphamide as neoadjuvant therapy in breast cancer: phase II trial

Research article

Patient self-appraisal of change and minimal clinically important difference on the European organization for the research and treatment of cancer quality of life questionnaire core 30 before and during cancer therapy

Study protocol

A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits